PatientsVille.com Logo

PatientsVille

Mucosta Side Effects

Common Mucosta Side Effects


The most commonly reported Mucosta side effects (click to view or check a box to report):

Pyrexia (15)
Liver Disorder (11)
Decreased Appetite (11)
Interstitial Lung Disease (9)
Shock (7)
Hepatic Function Abnormal (6)
Cerebral Haemorrhage (6)
Anaemia (6)
Abdominal Pain (5)
Ascites (5)
Death (5)
Nausea (4)
Multi-organ Failure (4)
Lung Disorder (4)
Oedema (4)
Rash (4)
White Blood Cell Count Increased (4)
Thrombocytopenia (4)
Septic Shock (4)
Platelet Count Decreased (4)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Mucosta Side Effects Reported to FDA

The following Mucosta reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Mucosta on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Blood Fibrinogen Decreased
This is a report of a 26-year-old male patient (weight: NA) from JP, suffering from the following symptoms/conditions: NA, who was treated with Mucosta (dosage: NA, start time: Sep 03, 2013), combined with:
  • Trisenox (.15 Milligram Daily;)
  • Trisenox
  • Trisenox
  • Trisenox
  • Trisenox
  • Bio-three
and developed a serious reaction and side effect(s). The consumer presented with:
  • Blood Fibrinogen Decreased
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Mucosta treatment in male patients, resulting in blood fibrinogen decreased side effect. The patient was hospitalized.

Depression
This report suggests a potential Mucosta Depression side effect(s) that can have serious consequences. A female patient (weight: NA) from DENMARK was diagnosed with the following symptoms/conditions: gastritis,insomnia,depression,sleep disorder,initial insomnia and used Mucosta (dosage: 200 Mg) starting Apr 04, 2012. Soon after starting Mucosta the patient began experiencing various side effects, including:
  • Depression
Drugs used concurrently:
  • Goodmin (0.25 Mg)
  • Lexapro (10 Mg)
  • Medipeace (1 Mg)
  • Amoban (7.5 Mg)
Although Mucosta demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as death, may still occur.

Depression
This Depression problem was reported by a health professional from DENMARK. A female patient (weight: NA) was diagnosed with the following symptoms/conditions: gastritis,initial insomnia,depression,sleep disorder. On Feb 09, 2012 this consumer started treatment with Mucosta (dosage: 200 Mg). The following drugs were being taken at the same time:
  • Amoban (7.5 Mg)
  • Lexapro (10 Mg)
  • Medipeace (1 Mg)
  • Goodmin (0.25 Mg)
When commencing Mucosta, the patient experienced the following unwanted symptoms/side effects:
  • Depression
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as death, may become evident only after a product is in use by the general population.

Lung Disorder
This is a report of a female patient (weight: NA) from JAPAN. The patient developed the following symptoms/conditions: NA and was treated with Mucosta (dosage: 300 Mg) starting Oct 23, 2011. Concurrently used drugs:
  • Lipitor (20 Mg)
  • Pradaxa (220 Mg)
  • Micardis (40 Mg)
  • Platibit
Soon after that, the consumer experienced the following side effects:
  • Lung Disorder
The patient was hospitalized. This opens a possibility that Mucosta treatment could cause the above reactions, including lung disorder, and some female subjects may be more susceptible.


Rash
A 68-year-old female patient (weight: NA) from JAPAN with the following symptoms/conditions: NA started Mucosta treatment (dosage: NA) on Mar 05, 2012. Soon after starting Mucosta treatment, the subject experienced various side effects, including:
  • Rash
Concurrently used drugs:
  • Peginterferon Alfa-2b
  • Allopurinol
  • Peginterferon Alfa-2b
  • Ribavirin
  • Telavic (telaprevir)
  • Evamyl
This finding indicates that some female patients could be more vulnerable to Mucosta.

Henoch-schonlein Purpura Nephritis
A 67-year-old female patient from JAPAN (weight: NA) experienced symptoms, such as: gastritis prophylaxis,rheumatoid arthritis,osteoporosis,hyperuricaemia,neuralgia,constipation and was treated with Mucosta(dosage: 100 Mg, 3x/day). The treatment was initiated on Feb 28, 2012. After that a consumer reported the following side effect(s):
  • Henoch-schonlein Purpura Nephritis
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Mucosta efficacy:
  • Enbrel (50 Mg, Weekly)
  • One-alpha (1 Ug, 1x/day)
  • Allopurinol (100 Mg, 1x/day)
  • Lyrica (75 Mg, 1x/day)
  • Magmitt (500 Mg, 3x/day)
  • Zantac (150 Mg, 1x/day)
  • Diovan (80 Mg, 1x/day)
  • Hokunalin /00654902/ (2 Mg, 2x/day)
The patient was hospitalized.

Papule, Lymphadenopathy, White Blood Cell Count Increased, Oedema, Lymphocytic Infiltration, Epidermal Necrosis, Liver Disorder, Pyrexia
In this report, Mucosta was administered for the following condition: sciatica.A 59-year-old male consumer from JAPAN (weight: NA) started Mucosta treatment (dosage: NA) on Jun 15, 2011.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Papule
  • Lymphadenopathy
  • White Blood Cell Count Increased
  • Oedema
  • Lymphocytic Infiltration
  • Epidermal Necrosis
  • Liver Disorder
  • Pyrexia
A possible interaction with other drugs could have contributed to this reaction:
  • Vitamin B12
  • Neurotropin
  • Tokishigyakukagoshuyushokyoto
  • Rinlaxer
  • Opalmon
  • Syakuyakukanzoto
  • Tegretol (200 Mg, Daily)
  • Voltaren (25 Mg, Daily)
The patient was hospitalized.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Mucosta treatment could be related to the listed above side effect(s).

Neuropathy Peripheral, Cardiac Failure Congestive, Cardiomyopathy, Stomatitis
This is a report of the following Mucosta side effect(s):
  • Neuropathy Peripheral
  • Cardiac Failure Congestive
  • Cardiomyopathy
  • Stomatitis
A female patient from JAPAN (weight: NA) presented with the following condition: prophylaxis against gastrointestinal ulcer,breast cancer metastatic,breast cancer recurrent and received a treatment with Mucosta (dosage: NA) starting: Mar 26, 2012.The following concurrently used drugs could have generated interactions:
  • Taxol
  • Avastin
The patient was hospitalized.This report suggests that a Mucosta treatment could be associated with the listed above side effect(s).

Thrombocytopenia, Haemorrhagic Diathesis, Coagulopathy, Pneumonia Aspiration, White Blood Cell Count Decreased, Beta 2 Microglobulin Increased, Brain Midline Shift, Histology Abnormal, Diffuse Large B-cell Lymphoma
This Mucosta report was submitted by a male consumer from JAPAN (weight: NA). The patient was diagnosed with: NA and Mucosta was administered (dosage: NA) starting: Feb 26, 2008. The consumer developed a set of symptoms:
  • Thrombocytopenia
  • Haemorrhagic Diathesis
  • Coagulopathy
  • Pneumonia Aspiration
  • White Blood Cell Count Decreased
  • Beta 2 Microglobulin Increased
  • Brain Midline Shift
  • Histology Abnormal
  • Diffuse Large B-cell Lymphoma
Other drugs used simultaneously:
  • Lendormin
  • Clarithromycin
  • Diazepam
  • Sodium Chloride
  • Sennoside
  • Omeprazole
  • Onealfa
  • Solu-medrol
The patient was hospitalized.Those unexpected symptoms could be linked to a Mucosta treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Platelet Count Increased, Hyperkalaemia, White Blood Cell Count Increased
This is a report of a possible correlation between Mucosta use and the following symptoms/side effect(s):
  • Platelet Count Increased
  • Hyperkalaemia
  • White Blood Cell Count Increased
which could contribute to an assessment of Mucosta risk profile.A 61-year-old male consumer from JP (weight: NA) was suffering from NA and was treated with Mucosta (dosage: 100 Mg, Uid/qd) starting Feb 20, 2012.Other concurrent medications:
  • Methycobal (500 Ug, Uid/qd)
  • Gasmotin (5 Mg, Uid/qd)
  • Magmitt (250 Mg, Uid/qd)
  • Berizym (1 Df, Uid/qd)
  • Seven E.p (1 Df, Uid/qd)
  • Strocain (5 Mg, Uid/qd)
  • Januvia (25 Mg, Uid/qd)
  • Amaryl (1 Mg, Uid/qd)
The patient was hospitalized.

Dyspnoea Exertional, Interstitial Lung Disease, Oedema, Decreased Appetite, Platelet Count Decreased, Blood Creatinine Increased, Blood Uric Acid Increased
A 65-year-old male patient from JAPAN (weight: NA) presented with the following symptoms: NA and after a treatment with Mucosta (dosage: NA) experienced the following side effect(s):
  • Dyspnoea Exertional
  • Interstitial Lung Disease
  • Oedema
  • Decreased Appetite
  • Platelet Count Decreased
  • Blood Creatinine Increased
  • Blood Uric Acid Increased
The treatment was started on Mar 13, 2012. Mucosta was used in combination with the following drugs:
  • Peg-intron (1.5 Mcg, Kg, Qw, Sc)
  • Telavic (antiviral Nos) (750 Mg, Tid, Po)
  • Ribavirin
  • Aldactone
  • Celestamine Tab
  • Interferon
  • Omeprazole
  • Sucralfate
The patient was hospitalized.This report could alert potential Mucosta consumers.

Insomnia, Headache, Rhinitis Allergic, Neutrophil Count Increased, Myocardial Infarction
In this report, a 50-year-old female patient from JAPAN (weight: NA) was affected by a possible Mucosta side effect.The patient was diagnosed with NA. After a treatment with Mucosta (dosage: Unk, start date: Aug 27, 2011), the patient experienced the following side effect(s):
  • Insomnia
  • Headache
  • Rhinitis Allergic
  • Neutrophil Count Increased
  • Myocardial Infarction
The following simultaneously used drugs could have led to this reaction:
  • Pursennid
  • Lansoprazole
  • Rozerem (Unk)
  • Romiplostim - Khk (3.57 Mug/kg, Qwk)
  • Lendormin
  • Prednisolone (11 Mg, Unk)
  • Alendronate Sodium (5 Mg, Unk)
  • Acetaminophen
The patient was hospitalized.The findings here stress that side effects should be taken into consideration when evaluating a Mucosta treatment.

Diabetes Mellitus Inadequate Control
This is a report of a 68-year-old male patient from JAPAN (weight: NA), who used Mucosta (dosage: NA) for a treatment of NA. After starting a treatment on NS, the patient experienced the following side effect(s):
  • Diabetes Mellitus Inadequate Control
The following drugs could possibly have interacted with the Mucosta treatment
  • Omeprazole
  • Lantus
  • Novolin R
  • Taurine
  • Lasix
  • Aldactone
  • Livact
  • Lulicon
The patient was hospitalized.Taken together, these observations suggest that a Mucosta treatment could be related to side effect(s), such as Diabetes Mellitus Inadequate Control.

Cerebral Infarction, Dysphagia
This cerebral infarction side effect was reported by a pharmacist from JAPAN. A 69-year-old female patient (weight:NA) experienced the following symptoms/conditions: NA. The patient was prescribed Mucosta (dosage: NA), which was started on Apr 02, 2012. Concurrently used drugs:
  • Mucosolvan
  • Theo-dur
  • Prednisolone
  • Lansoprazole
  • Magmitt
  • Tramadol Hydrochloride And Acetaminophen (3df Per Day)
When starting to take Mucosta the consumer reported the following symptoms:
  • Cerebral Infarction
  • Dysphagia
These side effects may potentially be related to Mucosta.

Pancytopenia, Interstitial Lung Disease
This is a Mucosta side effect report of a 64-year-old male patient (weight:NA) from JAPAN, suffering from the following symptoms/conditions: NA, who was treated with Mucosta (dosage:NA, start time: Feb 24, 2012), combined with:
  • Peg-intron
  • Famotidine
  • Mixed Ointment Of Myser And Salicylic Acid
  • Peg-intron
  • Telavic (telaprevir)
  • Peg-intron
  • Loxonin
  • Rebetol
, and developed a serious reaction and a pancytopenia side effect. The patient presented with:
  • Pancytopenia
  • Interstitial Lung Disease
which developed after the beginning of treatment. The patient was hospitalized. This side effect report can indicate a possible existence of increased vulnerability to Mucosta treatment in male patients suffering from NA, resulting in pancytopenia.

Thrombocytopenia, Perivascular Dermatitis, Renal Impairment, Pruritus, Purpura, Decreased Appetite, Prerenal Failure, Asthenia
This report suggests a potential Mucosta thrombocytopenia side effect(s) that can have serious consequences. A 57-year-old male patient from JAPAN (weight:NA) was diagnosed with the following health condition(s): NA and used Mucosta (dosage: NA) starting Feb 24, 2012. Soon after starting Mucosta the patient began experiencing various side effects, including:
  • Thrombocytopenia
  • Perivascular Dermatitis
  • Renal Impairment
  • Pruritus
  • Purpura
  • Decreased Appetite
  • Prerenal Failure
  • Asthenia
Drugs used concurrently:
  • Telavic (telaprevir)
  • Peg-intron
  • Atelec
  • Loxonin
  • Ribavirin
  • Peg-intron
  • Glycyron
  • Candesartan Cilexetil
The patient was hospitalized. Although Mucosta demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as thrombocytopenia, may still occur.

Productive Cough, Interstitial Lung Disease
This productive cough problem was reported by a physician from JAPAN. A 69-year-old female patient (weight: NA) was diagnosed with the following medical condition(s): gastritis,diabetes mellitus,sputum retention,nasopharyngitis.On Feb 17, 2011 a consumer started treatment with Mucosta (dosage: NA). The following drugs/medications were being taken at the same time:
  • Januvia
  • Mucosolvan
  • Dasen
When commencing Mucosta, the patient experienced the following unwanted symptoms /side effects:
  • Productive Cough
  • Interstitial Lung Disease
The patient was hospitalized. Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as productive cough, may become evident only after a product is in use by the general population.

Acute Myocardial Infarction, Cardiac Failure
This is a Mucosta (rebamipide) side effect report of a 76-year-old male patient (weight: NA) from JAPAN. The patient developed the following symptoms/conditions: NA and was treated with Mucosta (rebamipide) (dosage: NA) starting May 11, 2007. Concurrently used drugs:
  • Calblock (azelnidipine)
  • Rythmodan R (disopyramide Phosphate)
  • Alfarol (alfacalcidol)
  • Pletal (50 Mg, Tid)
  • Bufferin
  • Dorner (beraprost Sodium)
Soon after that, the consumer experienced the following of symptoms:
  • Acute Myocardial Infarction
  • Cardiac Failure
This opens a possibility that Mucosta (rebamipide) could cause acute myocardial infarction and that some male patients may be more susceptible.

Renal Cancer, Gastric Cancer
A 84-year-old female patient (weight: NA) from JAPAN with the following symptoms: NA started Mucosta (rebamipide) treatment (dosage: NA) on May 27, 2004. Soon after starting Mucosta (rebamipide) treatment, the consumer experienced several side effects, including:
  • Renal Cancer
  • Gastric Cancer
. Concurrently used drugs:
  • Amlodipine Besylate
  • Candesartan Cilexetil
  • Norvasc
  • Coniel (benidipine Hydrochloride)
  • Pletal (100 Mg, Bid, Oral)
This finding indicates that some patients can be more vulnerable to developing Mucosta (rebamipide) side effects, such as renal cancer.

Eosinophil Count Increased, Anaemia, Eosinophilic Pneumonia, Acute Myocardial Infarction, Platelet Count Decreased, Cardiac Failure Acute, Renal Failure, Condition Aggravated, Renal Artery Stenosis
This eosinophil count increased side effect was reported by a physician from JAPAN. A 76-year-old male patient (weight:NA) experienced the following symptoms/conditions: NA.The patient was prescribed Mucosta (rebamipide) Tablet (dosage: NA), which was started on May 11, 2007. Concurrently used drugs:
  • Calblock (azelnidipine) Tablet
  • Blopress (candesartan Cilexetil) Tablet
  • Nipolazin (mequitazine) Tablet
  • Argamate (calcium Polystyrene Sulfonate) Jelly
  • Allegra (fexofenadine Hydrochloride) Tablet
  • Pletal (50 Mg, Tid, Oral)
  • Rythmodan R (disopyramide Phosphate) Tablet
  • Alfarol (alfacalcidol) Capsule
.When starting to take Mucosta (rebamipide) Tablet the consumer reported symptoms, such as:
  • Eosinophil Count Increased
  • Anaemia
  • Eosinophilic Pneumonia
  • Acute Myocardial Infarction
  • Platelet Count Decreased
  • Cardiac Failure Acute
  • Renal Failure
  • Condition Aggravated
  • Renal Artery Stenosis
These side effects may potentially be related to Mucosta (rebamipide) Tablet. The patient was hospitalized.

Ventricular Extrasystoles
This is a report of a 69-year-old female patient (weight: NA) from JAPAN, suffering from the following symptoms/conditions: NA, who was treated with Mucosta (dosage: Unk, start time: Jan 06, 2011), combined with:
  • Novorapid (Unk)
  • Miglitol (50 Mg, 1x/day)
  • Lansoprazole (Unk)
  • Miglitol (50 Mg, 2x/day)
  • Novolin N (Unk)
  • Diovan (Unk)
  • Lipitor (Unk)
and developed a serious reaction and side effect(s). The consumer presented with:
  • Ventricular Extrasystoles
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Mucosta treatment in female patients, resulting in ventricular extrasystoles side effect.

Lung Consolidation, Interstitial Lung Disease, Cardiac Failure Acute, Malaise
This report suggests a potential Mucosta (rebamipide) Tablet, 100 Mg Lung Consolidation, Interstitial Lung Disease, Cardiac Failure Acute, Malaise side effect(s) that can have serious consequences. A 82-year-old male patient (weight: NA) from JAPAN was diagnosed with the following symptoms/conditions: NA and used Mucosta (rebamipide) Tablet, 100 Mg (dosage: NA) starting Nov 17, 2008. Soon after starting Mucosta (rebamipide) Tablet, 100 Mg the patient began experiencing various side effects, including:
  • Lung Consolidation
  • Interstitial Lung Disease
  • Cardiac Failure Acute
  • Malaise
Drugs used concurrently:
  • Pletal (100 Mg, Bid, Oral)
  • Magmitt (magnesium Oxide) Tablet, 330 Mg
  • Yodel-s (senna Extract) Tablet, 80 Mg
  • Aspirin
  • Prednisolone
  • Lansoprazole
  • Losartan Potassium
  • Amaryl
The patient was hospitalized. Although Mucosta (rebamipide) Tablet, 100 Mg demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as lung consolidation, may still occur.

Coma, Apallic Syndrome, Depressed Level Of Consciousness, Cerebral Haemorrhage, Hemiplegia, Agitation
This Coma, Apallic Syndrome, Depressed Level Of Consciousness, Cerebral Haemorrhage, Hemiplegia, Agitation problem was reported by a physician from JAPAN. A 87-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On Jul 17, 2003 this consumer started treatment with Mucosta (rebamipide) Tablet (dosage: NA). The following drugs were being taken at the same time:
  • Pletal (50 Mg, Bid, Oral)
When commencing Mucosta (rebamipide) Tablet, the patient experienced the following unwanted symptoms/side effects:
  • Coma
  • Apallic Syndrome
  • Depressed Level Of Consciousness
  • Cerebral Haemorrhage
  • Hemiplegia
  • Agitation
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as coma, may become evident only after a product is in use by the general population.

Liver Disorder, Pyrexia, Epidermal Necrosis, Lymphocytic Infiltration, Lymphocyte Stimulation Test Positive, Lymphadenopathy, Face Oedema, Extravasation Blood
This is a report of a 59-year-old male patient (weight: NA) from JAPAN. The patient developed the following symptoms/conditions: sciatica and was treated with Mucosta (dosage: NA) starting NS. Concurrently used drugs:
  • Syakuyakukanzoto
  • Tegretol
  • Voltaren
  • Rinlaxer
  • Opalmon
  • Tokishigyakukagoshuyushokyoto
  • Vitamin B12
  • Neurotropin
Soon after that, the consumer experienced the following side effects:
  • Liver Disorder
  • Pyrexia
  • Epidermal Necrosis
  • Lymphocytic Infiltration
  • Lymphocyte Stimulation Test Positive
  • Lymphadenopathy
  • Face Oedema
  • Extravasation Blood
This opens a possibility that Mucosta treatment could cause the above reactions, including liver disorder, and some male subjects may be more susceptible.

Haemorrhage, Melaena, Haematuria, Renal Failure Acute, Multi-organ Failure, Bacteraemia
A male patient (weight: NA) from JAPAN with the following symptoms/conditions: NA started Mucosta treatment (dosage: NA) on Mar 12, 2012. Soon after starting Mucosta treatment, the subject experienced various side effects, including:
  • Haemorrhage
  • Melaena
  • Haematuria
  • Renal Failure Acute
  • Multi-organ Failure
  • Bacteraemia
Concurrently used drugs:
  • Pradaxa (220 Mg)
  • Zosyn (13.5 Mg)
  • Novolin N (4 U)
  • Albuminar (100 Ml)
  • Vasoralan (80 Mg)
  • Celebrex (200 Mg)
  • Neophagen
  • Vancomycin Hydrochloride (2000 Mg)
The patient was hospitalized. This finding indicates that some male patients could be more vulnerable to Mucosta.

1 of 7 



Top 10 Mucosta Side Effects for Men

Men Side EffectsReports
Pyrexia 10
Decreased Appetite 7
Interstitial Lung Disease 6
Liver Disorder 6
Abdominal Pain 4
Shock 4
Anaemia 3
Ascites 3
Asthenia 3
Diarrhoea 3

Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Mucosta Side Effects

    Did You Have a Mucosta Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Mucosta for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Mucosta Safety Alerts, Active Ingredients, Usage Information

    More About Mucosta

    Side Effects reported to FDA: 169

    Mucosta safety alerts: No

    Reported deaths: 39

    Reported hospitalizations: 95

    Latest Mucosta clinical trials